Moderna and CytomX partner for mRNA-based conditnionally activated therapeutics
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Collaboration to generate and develop therapeutics for oncology and non-oncology conditions
Moderna and Merck announced mRNA-4157/V940, in combination with KEYTRUDA, demonstrated a 44% reduction in the risk of disease recurrence or death in melanoma patients
If approved, the vaccine could help simplify the meningococcal vaccination schedule and provide the broadest serogroup coverage of any meningococcal vaccine
The company has plans to launch this Vaccine by the end of 2023 after completing the required field studies and obtaining regulatory approvals
The vectored intranasal delivery platform gives us the capability for rapid product development, scale-up, easy and painless immunization during public health emergencies and pandemics
The company continue to develop this program for the WHO markets, thereby providing coverage and protection for more infants globally in time to come
Advent will also be making an open offer to acquire additional 26% of the outstanding equity shares of the company from the public shareholders.
Modi stressed the need to ensure that the entire Covid infrastructure at all levels is maintained at a high level of preparedness in terms of equipment, processes, and human resources
The newly built centre will work as the state-of-the-art facility for not just ethical animal studies but spans from basic, applied to regulatory animal research.
Subscribe To Our Newsletter & Stay Updated